サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1428229

オンコロジーバイオマーカーの世界市場レポート 2024年

Oncology Biomarkers Global Market Report 2024
出版日: 受注後更新 | 発行: The Business Research Company | ページ情報: 英文 175 Pages | 納期: 2～10営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円
オンコロジーバイオマーカーの世界市場レポート 2024年
出版日: 受注後更新
発行: The Business Research Company
ページ情報: 英文 175 Pages
納期: 2～10営業日
  • 全表示
  • 概要
  • 目次
概要

がんバイオマーカーの市場規模は、今後数年間で急速に成長すると予想されています。 2028年には13.6%の年間複合成長率（CAGR）で260億9,000万米ドルに成長すると予想されます。予測期間の拡大は、次世代シークエンシング（NGS）の統合、バイオマーカーインフォマティクスの拡大、予測薬理ゲノミクスの重視、エクソソームベースのバイオマーカーの急速な進歩、空間トランスクリプトミクスの採用によるものと考えられます。予測期間中に予想される注目すべき動向には、標準化と品質保証の取り組み、機能性バイオマーカーへの移行、臨床試験におけるバイオマーカーの重要性、免疫療法における応用の拡大、治療反応のリアルタイムモニタリングなどが含まれます。

がんバイオマーカー市場の予想される成長は、がんの発生率の増加によって促進されると予想されます。がんは、体内の特定の細胞が制御されずに増殖し、徐々に体の他の部分に広がることを特徴としています。がん的バイオマーカーは、個人の体内の遺伝子、タンパク質、その他の物質を分析することにより、がんの種類に関する詳細な情報を提供するという重要な役割を果たします。たとえば、2021年 2月に米国がん協会が発表した報告書では、2020年に推定1,930万人の新たながん症例と1,000万人近くのがん関連死亡が明らかになりました。さらに、2023年 3月の米国臨床がん会（ASCO）の報告書では、米国では毎年 1万2,000人以上が神経内分泌腫瘍と診断され、2023年には約17万1,000人がこの診断を受けながら生存することになります。したがって、がんの発生率の上昇により、がんバイオマーカー市場が推進されることになります。

がんバイオマーカーの成長に寄与する重要な要因は、個別化医療の採用の増加です。個別化医療は、患者一人ひとりの特性に合わせて医療を調整する革新的な医療アプローチです。 がんバイオマーカーのコンテキストでは、個別化医療は特定のバイオマーカーを利用して、個人のがんの固有の遺伝的または分子的特徴を特定します。実例として、2022年に食品医薬品局の医薬品評価研究センター（CDER）は37の新しい分子実体（NME）を承認し、その約34%（そのうち12個）は個別化医療連合（PMC）によって個別化医療として分類されました。したがって、個別化医療の採用の増加は、がんバイオマーカー市場の拡大の原動力として機能します。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 マクロ経済シナリオ

  • 高インフレが市場に与える影響
  • ウクライナ・ロシア戦争が市場に与える影響
  • COVID-19による市場への影響

第5章 世界市場規模と成長

  • 世界のがんバイオマーカー市場の促進要因と抑制要因
    • 市場促進要因
    • 市場抑制要因
  • 世界のがんバイオマーカーの市場規模実績と成長、2018～2023年
  • 世界のがんバイオマーカー市場規模と成長予測、2023～2028年、2033年

第6章 市場セグメンテーション

  • 世界のがんバイオマーカー市場、バイオマーカーのタイプ別セグメンテーション、実績と予測、2018～2023年、2023～2028年、2033年
  • タンパク質バイオマーカー
  • 遺伝的バイオマーカー
  • その他
  • 世界のがんバイオマーカー市場、プロファイリング技術別セグメンテーション、実績と予測、2018～2023年、2023～2028年、2033年
  • Omics技術
  • イメージング技術
  • 免疫測定法
  • バイオインフォマティクス
  • その他
  • 世界のがんバイオマーカー市場、がんタイプ別セグメンテーション、実績と予測、2018～2023年、2023～2028年、2033年
  • 乳がん
  • 肺がん
  • 結腸直腸がん
  • 前立腺がん
  • 黒色腫
  • 白血病
  • 卵巣がん
  • 肝臓がん
  • その他
  • 世界のがんバイオマーカー市場、用途別セグメンテーション、実績と予測、2018～2023年、2023～2028年、2033年
  • 診断
  • 研究開発
  • 予後
  • リスクアセスメント
  • その他
  • 世界のがんバイオマーカー市場、エンドユーザー別セグメンテーション、実績と予測、2018～2023年、2023～2028年、2033年
  • 病院
  • 学術とがん研究機関
  • 外来手術センター
  • 診断ラボ

第7章 地域と国の分析

  • 世界のがんバイオマーカー市場、地域別、実績と予測、2018～2023年、2023～2028年、2033年
  • 世界のがんバイオマーカー市場、国別、実績と予測、2018～2023年、2023～2028年、2033年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

  • がんバイオマーカー市場の競合情勢
  • がんバイオマーカー市場の企業プロファイル
    • F Hoffmann-La Roche AG
    • Novartis AG
    • Thermo Fisher Scientific Inc.
    • Abbott Laboratories
    • Eli Lilly and Company

第31章 その他の大手と革新的な企業

  • Merck KGaA
  • Siemens Healthcare GmbH
  • Becton Dickinson and Company
  • GE Healthcare Technologies Inc.
  • Eurofins Scientific SE
  • Agilent Technologies Inc.
  • Hologic Inc.
  • Illumina Inc.
  • Charles River Laboratories International Inc.
  • bioMerieux SA
  • Bio-Rad Laboratories Inc.
  • Bruker Corporation
  • QIAGEN NV
  • Exact Sciences Corporation
  • Sysmex Corporation

第32章 競合ベンチマーキング

第33章 競合ダッシュボード

第34章 主要な合併と買収

第35章 将来の展望と潜在性分析

第36章 付録

目次
Product Code: r14073

Oncology biomarkers are biological molecules within a patient's body indicating the presence of cancer. These biomarkers offer insights into the occurrence of cancer in an individual.

The primary categories of oncology biomarkers include protein biomarkers, genetic biomarkers, and others. Protein biomarkers involve the use of one or multiple proteins for diagnosing diseases, understanding prognosis, and monitoring a patient's biological response to treatment. Profiling technologies encompass omics technologies, imaging technologies, immunoassays, bioinformatics, and others. Cancer types covered by oncology biomarkers include breast cancer, lung cancer, colorectal cancer, prostate cancer, melanoma, leukemia, ovarian cancer, liver cancer, and others. These biomarkers find various applications such as diagnostics, research and development, prognostics, risk assessment, and more, predominantly utilized in hospitals, academic and cancer research institutes, ambulatory surgical centers, and diagnostic laboratories.

The oncology biomarkers market research report is one of a series of new reports from The Business Research Company that provides oncology biomarkers market statistics, including oncology biomarkers industry global market size, regional shares, competitors with a oncology biomarkers market share, detailed oncology biomarkers market segments, market trends and opportunities, and any further data you may need to thrive in the oncology biomarkers industry. This oncology biomarkers market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The oncology biomarkers market size has grown rapidly in recent years. It will grow from $13.68 billion in 2023 to $15.69 billion in 2024 at a compound annual growth rate (CAGR) of 14.7%. The rise observed in the historical period can be credited to the adoption in emerging economies, precision medicine initiatives, advancements in diagnostics, support for drug development, and the increased incidence of cancer.

The oncology biomarkers market size is expected to see rapid growth in the next few years. It will grow to $26.09 billion in 2028 at a compound annual growth rate (CAGR) of 13.6%. The anticipated expansion in the forecast period can be ascribed to the integration of next-generation sequencing (NGS), the extension of biomarker informatics, emphasis on predictive pharmacogenomics, swift progress in exosome-based biomarkers, and the adoption of spatial transcriptomics. Noteworthy trends expected in the forecast period encompass the standardization and quality assurance efforts, a transition towards functional biomarkers, the significance of biomarkers in clinical trials, the broadened applications in immunotherapy, and the real-time monitoring of treatment responses.

The anticipated growth in the oncology biomarker market is expected to be driven by the increasing incidence of cancer. Cancer is characterized by the uncontrolled growth of certain cells in the body, gradually spreading to other parts of the body. Oncological biomarkers play a crucial role in providing detailed information about the type of cancer by analyzing genes, proteins, and other substances within an individual's body. For instance, a report published by the American Cancer Society in February 2021 revealed an estimated 19.3 million new cancer cases and nearly 10.0 million cancer-related deaths in 2020. Additionally, reports from the American Society of Clinical Oncology (ASCO) in March 2023 estimated that over 12,000 individuals in the US were diagnosed with neuroendocrine tumors annually, with approximately 171,000 people living with this diagnosis in 2023. Thus, the rising incidence of cancer is poised to propel the oncology biomarker market.

The significant factor contributing to the growth of oncology biomarkers is the increasing adoption of personalized medicine. Personalized medicine is an innovative healthcare approach that tailors medical treatment to the individual characteristics of each patient. In the context of oncology biomarkers, personalized medicine utilizes specific biomarkers to identify unique genetic or molecular characteristics of an individual's cancer. As an illustration, in 2022, the Food and Drug Administration's Center for Drug Evaluation and Research (CDER) approved 37 new molecular entities (NMEs), with approximately 34% (12 of them) classified as personalized medicines by the Personalized Medicine Coalition (PMC). Hence, the growing adoption of personalized medicine serves as a driving force for the expansion of the oncology biomarker market.

The adoption of innovative and advanced technologies stands out as a prominent trend in the oncology biomarker market. Leading companies in this market are actively introducing new and groundbreaking technologies to enhance their position. In 2022, OncoDNA, a Belgium-based precision medicine company in oncology, launched OncoDEEP, a distinctive kit designed for laboratories to conduct comprehensive biomarker testing. OncoDEEP utilizes Next-generation sequencing (NGS) technology and cloud-based software tools, empowering laboratories to perform large-panel sequencing, acquire the molecular characterization of tumors, analyze raw data, and access robust quality controls.

Major players in the oncology biomarkers market are also focused on developing innovative products, such as clinical assays, to gain a competitive advantage. Clinical assays are biochemical tests used in healthcare to measure the presence or amount of a specific substance in biological samples such as blood, tissue, or urine. For instance, in December 2022, Adaptive Biotechnologies, a US-based biotechnology company, introduced the clonoSEQ Assay for detecting minimal residual disease (MRD) in blood for patients with diffuse large B-cell lymphoma (DLBCL). Leveraging circulating tumor DNA (ctDNA), clonoSEQ enables the assessment of MRD status in DLBCL, providing clinicians with a sensitive and quantitative measure of disease burden for earlier relapse detection and more precise treatment planning. Notably, it is the first and only MRD test in DLBCL with Medicare coverage across all lines of therapy, treatment regimens, and timepoints.

In May 2023, Freenome, a US-based biotech company, completed the acquisition of Oncimmune Ltd., a UK-based company specializing in developing immunodiagnostics. This strategic acquisition is poised to enhance Freenome's cancer screening efforts by providing additional clinical and commercial resources. Moreover, it will contribute to augmenting Freenome's multi-omics platform, offering a more comprehensive view of the tumor microenvironment.

Major companies operating in the oncology biomarkers market report are F Hoffmann-La Roche AG, Novartis AG, Thermo Fisher Scientific Inc., Abbott Laboratories, Eli Lilly and Company, Merck KGaA, Siemens Healthcare GmbH, Becton Dickinson and Company, GE Healthcare Technologies Inc., Eurofins Scientific SE, Agilent Technologies Inc., Hologic Inc., Illumina Inc., Charles River Laboratories International Inc., bioMerieux SA, Bio-Rad Laboratories Inc., Bruker Corporation, QIAGEN NV, Exact Sciences Corporation, Sysmex Corporation, PerkinElmer Inc., Leica Biosystems, Myriad Genetics Inc., Guardant Health Inc., Enzo Biochem Inc., Biocartis Group NV, Bristol -Myers Squibb Company, Agendia Inc., Epigenomics AG, OncoDNA SA.

North America was the largest region in the oncology biomarkers market in 2023. The regions covered in the oncology biomarkers market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the oncology biomarkers market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.

The oncology biomarkers market consists of sales of epigenetic biomarkers, metabolic biomarkers and proteomic biomarkers. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Oncology Biomarkers Global Market Report 2024 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on oncology biomarkers market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
  • Understand how the market has been affected by the coronavirus and how it is responding as the impact of the virus abates.
  • Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
  • Measure the impact of high global inflation on market growth.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for oncology biomarkers ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The oncology biomarkers market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include:

The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.

The impact of higher inflation in many countries and the resulting spike in interest rates.

The continued but declining impact of covid 19 on supply chains and consumption patterns.

  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:

  • 1) By Biomarker Type: Protein Biomarkers; Genetic Biomarkers; Other Cancer Biomarkers
  • 2) By Profiling Technologies: Omics Technologies; Imaging Technologies; Immunoassay; Bioinformatics; Other Profiling Technologies
  • 3) By Cancer Type: Breast Cancer; Lung Cancer; Colorectal Cancer; Prostate Cancer; Melanoma; Leukemia; Ovarian Cancer; Liver Cancer; Other Cancer Types
  • 4) By Application: Diagnostics; Research And Development; Prognostics; Risk Assessment; Other Applications
  • 5) By End-User: Hospitals; Academic And Cancer Research Institutes; Ambulatory Surgical Centers; Diagnostic Laboratories
  • Companies Mentioned: F Hoffmann-La Roche AG; Novartis AG; Thermo Fisher Scientific Inc.; Abbott Laboratories; Eli Lilly and Company
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Oncology Biomarkers Market Characteristics

3. Oncology Biomarkers Market Trends And Strategies

4. Oncology Biomarkers Market - Macro Economic Scenario

  • 4.1. Impact Of High Inflation On The Market
  • 4.2. Ukraine-Russia War Impact On The Market
  • 4.3. COVID-19 Impact On The Market

5. Global Oncology Biomarkers Market Size and Growth

  • 5.1. Global Oncology Biomarkers Market Drivers and Restraints
    • 5.1.1. Drivers Of The Market
    • 5.1.2. Restraints Of The Market
  • 5.2. Global Oncology Biomarkers Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
  • 5.3. Global Oncology Biomarkers Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Oncology Biomarkers Market Segmentation

  • 6.1. Global Oncology Biomarkers Market, Segmentation By Biomarker Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Protein Biomarkers
  • Genetic Biomarkers
  • Other Cancer Biomarkers
  • 6.2. Global Oncology Biomarkers Market, Segmentation By Profiling Technologies, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Omics Technologies
  • Imaging Technologies
  • Immunoassay
  • Bioinformatics
  • Other Profiling Technologies
  • 6.3. Global Oncology Biomarkers Market, Segmentation By Cancer Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Breast Cancer
  • Lung Cancer
  • Colorectal Cancer
  • Prostate Cancer
  • Melanoma
  • Leukemia
  • Ovarian Cancer
  • Liver Cancer
  • Other Cancer Types
  • 6.4. Global Oncology Biomarkers Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Diagnostics
  • Research And Development
  • Prognostics
  • Risk Assessment
  • Other Applications
  • 6.5. Global Oncology Biomarkers Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Hospitals
  • Academic And Cancer Research Institutes
  • Ambulatory Surgical Centers
  • Diagnostic Laboratories

7. Oncology Biomarkers Market Regional And Country Analysis

  • 7.1. Global Oncology Biomarkers Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 7.2. Global Oncology Biomarkers Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Oncology Biomarkers Market

  • 8.1. Asia-Pacific Oncology Biomarkers Market Overview
  • Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific Oncology Biomarkers Market, Segmentation By Biomarker Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 8.3. Asia-Pacific Oncology Biomarkers Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 8.4. Asia-Pacific Oncology Biomarkers Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Oncology Biomarkers Market

  • 9.1. China Oncology Biomarkers Market Overview
  • 9.2. China Oncology Biomarkers Market, Segmentation By Biomarker Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
  • 9.3. China Oncology Biomarkers Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
  • 9.4. China Oncology Biomarkers Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Oncology Biomarkers Market

  • 10.1. India Oncology Biomarkers Market, Segmentation By Biomarker Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 10.2. India Oncology Biomarkers Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 10.3. India Oncology Biomarkers Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Oncology Biomarkers Market

  • 11.1. Japan Oncology Biomarkers Market Overview
  • 11.2. Japan Oncology Biomarkers Market, Segmentation By Biomarker Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 11.3. Japan Oncology Biomarkers Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 11.4. Japan Oncology Biomarkers Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Oncology Biomarkers Market

  • 12.1. Australia Oncology Biomarkers Market, Segmentation By Biomarker Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 12.2. Australia Oncology Biomarkers Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 12.3. Australia Oncology Biomarkers Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Oncology Biomarkers Market

  • 13.1. Indonesia Oncology Biomarkers Market, Segmentation By Biomarker Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 13.2. Indonesia Oncology Biomarkers Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 13.3. Indonesia Oncology Biomarkers Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Oncology Biomarkers Market

  • 14.1. South Korea Oncology Biomarkers Market Overview
  • 14.2. South Korea Oncology Biomarkers Market, Segmentation By Biomarker Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 14.3. South Korea Oncology Biomarkers Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 14.4. South Korea Oncology Biomarkers Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Oncology Biomarkers Market

  • 15.1. Western Europe Oncology Biomarkers Market Overview
  • 15.2. Western Europe Oncology Biomarkers Market, Segmentation By Biomarker Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 15.3. Western Europe Oncology Biomarkers Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 15.4. Western Europe Oncology Biomarkers Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Oncology Biomarkers Market

  • 16.1. UK Oncology Biomarkers Market, Segmentation By Biomarker Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 16.2. UK Oncology Biomarkers Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 16.3. UK Oncology Biomarkers Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Oncology Biomarkers Market

  • 17.1. Germany Oncology Biomarkers Market, Segmentation By Biomarker Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 17.2. Germany Oncology Biomarkers Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 17.3. Germany Oncology Biomarkers Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Oncology Biomarkers Market

  • 18.1. France Oncology Biomarkers Market, Segmentation By Biomarker Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 18.2. France Oncology Biomarkers Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 18.3. France Oncology Biomarkers Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Oncology Biomarkers Market

  • 19.1. Italy Oncology Biomarkers Market, Segmentation By Biomarker Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 19.2. Italy Oncology Biomarkers Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 19.3. Italy Oncology Biomarkers Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Oncology Biomarkers Market

  • 20.1. Spain Oncology Biomarkers Market, Segmentation By Biomarker Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 20.2. Spain Oncology Biomarkers Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 20.3. Spain Oncology Biomarkers Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Oncology Biomarkers Market

  • 21.1. Eastern Europe Oncology Biomarkers Market Overview
  • 21.2. Eastern Europe Oncology Biomarkers Market, Segmentation By Biomarker Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 21.3. Eastern Europe Oncology Biomarkers Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 21.4. Eastern Europe Oncology Biomarkers Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Oncology Biomarkers Market

  • 22.1. Russia Oncology Biomarkers Market, Segmentation By Biomarker Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 22.2. Russia Oncology Biomarkers Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 22.3. Russia Oncology Biomarkers Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Oncology Biomarkers Market

  • 23.1. North America Oncology Biomarkers Market Overview
  • 23.2. North America Oncology Biomarkers Market, Segmentation By Biomarker Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 23.3. North America Oncology Biomarkers Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 23.4. North America Oncology Biomarkers Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Oncology Biomarkers Market

  • 24.1. USA Oncology Biomarkers Market Overview
  • 24.2. USA Oncology Biomarkers Market, Segmentation By Biomarker Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 24.3. USA Oncology Biomarkers Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 24.4. USA Oncology Biomarkers Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Oncology Biomarkers Market

  • 25.1. Canada Oncology Biomarkers Market Overview
  • 25.2. Canada Oncology Biomarkers Market, Segmentation By Biomarker Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 25.3. Canada Oncology Biomarkers Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 25.4. Canada Oncology Biomarkers Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Oncology Biomarkers Market

  • 26.1. South America Oncology Biomarkers Market Overview
  • 26.2. South America Oncology Biomarkers Market, Segmentation By Biomarker Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 26.3. South America Oncology Biomarkers Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 26.4. South America Oncology Biomarkers Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Oncology Biomarkers Market

  • 27.1. Brazil Oncology Biomarkers Market, Segmentation By Biomarker Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 27.2. Brazil Oncology Biomarkers Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 27.3. Brazil Oncology Biomarkers Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Oncology Biomarkers Market

  • 28.1. Middle East Oncology Biomarkers Market Overview
  • 28.2. Middle East Oncology Biomarkers Market, Segmentation By Biomarker Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 28.3. Middle East Oncology Biomarkers Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 28.4. Middle East Oncology Biomarkers Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Oncology Biomarkers Market

  • 29.1. Africa Oncology Biomarkers Market Overview
  • 29.2. Africa Oncology Biomarkers Market, Segmentation By Biomarker Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 29.3. Africa Oncology Biomarkers Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 29.4. Africa Oncology Biomarkers Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Oncology Biomarkers Market Competitive Landscape And Company Profiles

  • 30.1. Oncology Biomarkers Market Competitive Landscape
  • 30.2. Oncology Biomarkers Market Company Profiles
    • 30.2.1. F Hoffmann-La Roche AG
      • 30.2.1.1. Overview
      • 30.2.1.2. Products and Services
      • 30.2.1.3. Strategy
      • 30.2.1.4. Financial Performance
    • 30.2.2. Novartis AG
      • 30.2.2.1. Overview
      • 30.2.2.2. Products and Services
      • 30.2.2.3. Strategy
      • 30.2.2.4. Financial Performance
    • 30.2.3. Thermo Fisher Scientific Inc.
      • 30.2.3.1. Overview
      • 30.2.3.2. Products and Services
      • 30.2.3.3. Strategy
      • 30.2.3.4. Financial Performance
    • 30.2.4. Abbott Laboratories
      • 30.2.4.1. Overview
      • 30.2.4.2. Products and Services
      • 30.2.4.3. Strategy
      • 30.2.4.4. Financial Performance
    • 30.2.5. Eli Lilly and Company
      • 30.2.5.1. Overview
      • 30.2.5.2. Products and Services
      • 30.2.5.3. Strategy
      • 30.2.5.4. Financial Performance

31. Oncology Biomarkers Market Other Major And Innovative Companies

  • 31.1. Merck KGaA
  • 31.2. Siemens Healthcare GmbH
  • 31.3. Becton Dickinson and Company
  • 31.4. GE Healthcare Technologies Inc.
  • 31.5. Eurofins Scientific SE
  • 31.6. Agilent Technologies Inc.
  • 31.7. Hologic Inc.
  • 31.8. Illumina Inc.
  • 31.9. Charles River Laboratories International Inc.
  • 31.10. bioMerieux SA
  • 31.11. Bio-Rad Laboratories Inc.
  • 31.12. Bruker Corporation
  • 31.13. QIAGEN NV
  • 31.14. Exact Sciences Corporation
  • 31.15. Sysmex Corporation

32. Global Oncology Biomarkers Market Competitive Benchmarking

33. Global Oncology Biomarkers Market Competitive Dashboard

34. Key Mergers And Acquisitions In The Oncology Biomarkers Market

35. Oncology Biomarkers Market Future Outlook and Potential Analysis

  • 35.1 Oncology Biomarkers Market In 2028 - Countries Offering Most New Opportunities
  • 35.2 Oncology Biomarkers Market In 2028 - Segments Offering Most New Opportunities
  • 35.3 Oncology Biomarkers Market In 2028 - Growth Strategies
    • 35.3.1 Market Trend Based Strategies
    • 35.3.2 Competitor Strategies

36. Appendix

  • 36.1. Abbreviations
  • 36.2. Currencies
  • 36.3. Historic And Forecast Inflation Rates
  • 36.4. Research Inquiries
  • 36.5. The Business Research Company
  • 36.6. Copyright And Disclaimer